Intelligence Engineered for Traders

FEATURED BY:

  • Brand 1
  • Brand 2
  • Brand 3
  • Brand 4
  • Brand 5
  • Brand 6
  • Brand 7
  • Brand 8
  • Brand 9
  • Brand 10
  • Brand 11
Intuitive Surgical’s 22.5% Monthly Rally Spurs Valuation Debate

Intuitive Surgical’s 22.5% Monthly Rally Spurs Valuation Debate

Dorian Wells November 19, 2025 6:15 AM

Intuitive Surgical (NYSE:ISRG) surged 22.5% over the past month, sparking a fresh debate about its valuation and growth runway. The move matters now because short-term momentum has pushed the stock back toward analyst targets while investors prepare for another earnings cycle. In the short term, trading signals and product rollouts are driving price action. In the long term, adoption of surgical robotics and hospital partnerships will determine revenue growth. U.S.

Read More »
AI Infrastructure Lift: Amphenol, Broadcom Gain Momentum While Microsoft and Oracle Face Short-Term Pressure

AI Infrastructure Lift: Amphenol, Broadcom Gain Momentum While Microsoft and Oracle Face Short-Term Pressure

Nathan Cook November 19, 2025 6:13 AM

AI infrastructure names are driving market action this week. Data-center demand is reshaping order books, analyst views and price targets for hardware suppliers. In the short term, Nvidia earnings and related semiconductor reactions are creating volatility across stocks tied to AI stacks. Over the long term, secular cloud and AI capex should support chassis, connector and software vendors. The U.S. market is most directly affected, but European and Asian data-center

Read More »
AI Frenzy Faces a Reality Check as Nvidia Earnings, Apple China Surge and Cloud Deals Rewire Flows

AI Frenzy Faces a Reality Check as Nvidia Earnings, Apple China Surge and Cloud Deals Rewire Flows

Elliot Drayton November 19, 2025 6:13 AM

Markets Test AI Mania as Nvidia Earnings and Apple Momentum Collide Global markets paused this week as investors weighed an AI-driven valuation reset against fresh demand signals from Apple (NASDAQ:AAPL). Short-term, Nvidia (NASDAQ:NVDA) earnings and US jobs data are driving volatility. Long-term, cloud commitments and infrastructure financing are shaping capital spend for years. The US and Europe show risk-off trading; Asia is mixed but Apple’s 25% China share signals local

Read More »
Heavyweights Face a Reality Check as Markets Reprice Risk

Heavyweights Face a Reality Check as Markets Reprice Risk

Harper Langston November 19, 2025 6:12 AM

Markets this week pivoted toward a more cautious tone as several anchor groups that investors rely on for steady returns began to show cracks. A concentrated pullback in bank stocks — highlighted by a 4.5% drop in the KBW Bank Index over the last five trading sessions compared with a 2.9% decline for the S&P 500 over the same span — has forced a re-evaluation of how much of this

Read More »
Novo Nordisk Lowers Ozempic and Wegovy Prices

Novo Nordisk Lowers Ozempic and Wegovy Prices

Dorian Wells November 19, 2025 6:11 AM

Novo Nordisk cuts GLP-1 prices to regain U.S. market share. The company lowered the standard monthly cash price for Wegovy and Ozempic from $499 to $349 and launched a $199 introductory offer for two months for self-pay patients through March 31; the top Ozempic dose will remain $499. This matters now because a recent Medicare coverage deal and a White House pricing portal are intensifying competition with Eli Lilly (NYSE:LLY)

Read More »

THE LATEST

THE LATEST

TRADE ENGINE

ABOUT US

PRIVACY POLICY

TERMS AND CONDITIONS

Facebook Youtube Linkedin X-twitter tiktok Instagram